Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | MELK | Q14680 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568143 | 0.82 | MELK (0.46) | MELKKDM1AMAOAACKR3CYP3A4 | |
| SCHEMBL21043709 | 0.73 | HSD11B1 (0.39) | KDM1AMAOACYP3A4CHRNB4CHRNA3 | |
| SCHEMBL259311 | 0.71 | MEN1 (0.65) | CYP3A4CYP2C9NTRK1 | |
| SCHEMBL18789836 | 0.71 | CYP3A4 (0.63) | MELKCYP3A4CYP19A1CYP2C9NAMPT | |
| SCHEMBL28304288 | 0.70 | RAB9A (0.62) | ROCK1PIM1PIM3PIM2NAMPT | |
| SCHEMBL18843417 | 0.70 | NPC1 (0.57) | ROCK1 | |
| SCHEMBL601922 | 0.70 | ROCK1 (0.59) | ROCK1PIM1PIM3PIM2NAMPT | |
| SCHEMBL21695760 | 0.68 | FADS1 (0.53) | ROCK1PIM1PIM3PIM2NTRK1 | |
| SCHEMBL21348467 | 0.68 | CHRNB4 (0.53) | ACKR3NAMPTHDAC3HDAC11HDAC8 | |
| SCHEMBL4888537 | 0.68 | KDM4E (0.65) | ROCK1PIM1PIM3PIM2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169233-B2 | Methods for the preparation of aryl amides | SYNGENTA LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| EP-2373625-B1 | METHODS FOR THE PREPARATION OF ARYL AMIDES | SYNGENTA LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-20140107348-A1 | METHODS FOR THE PREPARATION OF ARYL AMIDES | SYNGENTA LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8680337-B2 | Process for the production of amides | Sungenta Limited (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8637678-B2 | Methods for the preparation of aryl amides | SYNGENTA LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130253225-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-8436037-B2 | Process for the production of amides | SYNGENTA LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| EP-1928838-B1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120065239-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-20110263869-A1 | METHODS FOR THE PREPARATION OF ARYL AMIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2373625-A1 | METHODS FOR THE PREPARATION OF ARYL AMIDES | Syngenta Limited (GB) | 2011-10-12 | — | — | EP | disclosed |
| EP-2370412-A1 | METHODS FOR THE PREPARATION OF FUNGICIDES | Syngenta Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| US-7994341-B2 | Process for the production of amides | SYNGENTA LIMITED (GB) | 2011-08-09 | — | — | US | disclosed |
| EP-2253623-A1 | New crystal form of a pyrazole fungicide | Syngenta Participations AG. (CH) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253622-A1 | Process for the production of amides | Syngenta Participations AG. (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010072631-A1 | METHODS FOR THE PREPARATION OF FUNGICIDES | SYNGENTA LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072632-A1 | METHODS FOR THE PREPARATION OF ARYL AMIDES | SYNGENTA LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
| US-20090163569-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1928838-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | Syngeta Participations AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007031323-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA PARTICIPATIONS AG. (CH) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107348-A1 | METHODS FOR THE PREPARATION OF ARYL AMIDES | SOD1, CBR3, AOC3 | CHRNB2 4543/4885CHRNA4 4154/4885MELK 3884/4885 |
| US-20110263869-A1 | METHODS FOR THE PREPARATION OF ARYL AMIDES | SOD1, AOC3, CBR3 | CHRNB2 4382/4885CHRNA4 3857/4885MELK 3870/4885 |
| US-20120065239-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | CFH, C5, CFB | CHRNB2 3072/4885CHRNA4 3201/4885MELK 4558/4885 |
| US-20130253225-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | CFH, C5, CFB | CHRNB2 3175/4885CHRNA4 3287/4885MELK 4586/4885 |
| US-20090163569-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | C5, CFH, C9 | CHRNB2 2716/4885CHRNA4 3024/4885MELK 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.